Well, Tondo, I know that most people are more and more concerned that bacteria are building up resistances to existing antibiotics faster tahtn we can
come up iwht new ones.
I think there're two reasons for this.
First, doctors tend to give in to patients who want an antibiotic for a disease which is probably viral in nature. Of course, antibiotics
don't work against viral diseases, just against bacterial ones. So a lot of people are getting antibiotics whentthey don't need them, and the
bacteria are getting another chance to mutate.
Second, antibiotics are not an easy thing to produce, since the government has imposed a huge series of roadblocks to quick deployment of a
drug. There's nothing necessarily wrong with that; if you remember that mutagenic drug Thalidomide given to pregnant women back in the fifties and
sixties that caused kids to be born with undeveloped arms, you tend to like the idea of being careful!
Nonetheless, given that, when you amortize the drug ingredients that don't make it, it takes up to a billion (yep, that's the number with the
"B") dollars to develop a drug and take it through the testing cycle, a company is not going to spend that kind of money to develop a drug and see
its ability to make them a profit taken away within four or five years.
That's why Pfizer's Z-pak (zithromax), probably one of the best antibiotics around, costs so much -- because there isn't a generic version yet.
And most peoples' insurance won't pay for the Z-pak, which is a lot.
But pretty soon the patent on Z-pak will go away, and you will see a lot of those same kind of macrolide antibiotics, and the price will go down.
The bad news is that Pfizer, unless it makes a good profit on Z-pak, is probably not going to invest millions and millions of dollars to come up with
another drug the formula of which will be made public.
So we son't be seeing a lot of new drugs on the market unless either the Government makes it easier to get these new drugs to market, ensures that
the original manufacturer gets to keep the proprietary right to the drug, or both.




